Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10297289" target="_blank" >RIV/00216208:11110/15:10297289 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10297289

Výsledek na webu

<a href="http://dx.doi.org/10.1093/ndt/gfv215" target="_blank" >http://dx.doi.org/10.1093/ndt/gfv215</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/ndt/gfv215" target="_blank" >10.1093/ndt/gfv215</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?

Popis výsledku v původním jazyce

Experience with rituximab in patients with new ANCA-associated vasculitis (AAV) is still very limited, especially in patients with severe (organ- or life-threatening) AAV. Rituximab may be more effective in anti-PR3 AAV, but potentially less effective insome granulomatous manifestations of AAV. We do not know what the response is to rituximab on the tissue level. Rituximab induction needs to be followed by maintenance treatment, and potentially very long rituximab maintenance may result in higher riskof rituximab-related complications (e.g. decrease in IgG levels). Long-term experience with rituximab in AAV is insufficient. Treatment with rituximab is more expensive than the standard treatment with cyclophosphamide and corticosteroids and seems to becost-effective only in patients primarily treated with cyclophosphamide. Rituximab can be used in some newly diagnosed patients with AAV (e.g. women with child-bearing potential, or patients with active vasculitis and severe infection),

Název v anglickém jazyce

Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?

Popis výsledku anglicky

Experience with rituximab in patients with new ANCA-associated vasculitis (AAV) is still very limited, especially in patients with severe (organ- or life-threatening) AAV. Rituximab may be more effective in anti-PR3 AAV, but potentially less effective insome granulomatous manifestations of AAV. We do not know what the response is to rituximab on the tissue level. Rituximab induction needs to be followed by maintenance treatment, and potentially very long rituximab maintenance may result in higher riskof rituximab-related complications (e.g. decrease in IgG levels). Long-term experience with rituximab in AAV is insufficient. Treatment with rituximab is more expensive than the standard treatment with cyclophosphamide and corticosteroids and seems to becost-effective only in patients primarily treated with cyclophosphamide. Rituximab can be used in some newly diagnosed patients with AAV (e.g. women with child-bearing potential, or patients with active vasculitis and severe infection),

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Nephrology Dialysis Transplantation

ISSN

0931-0509

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

7

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

3

Strana od-do

1088-1090

Kód UT WoS článku

000359780300009

EID výsledku v databázi Scopus

2-s2.0-84936804172